CTOs on the Move

Pacific Biosciences

www.pacb.com

 
Pacific Biosciences is developing an environment in which scientists can seamlessly integrate multiple data types from multiple sources and deploy advanced bioinformatics methods to elucidate the complexity of living systems. Therefore, we are committed
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.pacb.com
  • 1380 Willow Rd
    Menlo Park, CA USA 94025
  • Phone: 650.521.8000

Executives

Name Title Contact Details
Tobias Mann
Vice President of Software Engineering Profile

Funding

Pacific Biosciences raised $900M on 02/10/2021

Similar Companies

Kinsbursky Brothers

Kinsbursky Brothers is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ariana Pharma

Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.

Zacharon

Zacharon is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TLC Biopharmaceuticals

TLC Biopharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients` lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme`s commercially-validated solution has touched more than 500,000 patient lives in post-marketing use via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme`s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company`s partners make progress developing and commercializing their products being developed using ENHANZE®